Philadelphia, PA, November 24, 2025
Ladder Bio Inc., previously known as ThirdLaw Molecular, has announced a rebranding to enhance its focus on developing innovative therapeutics for disease-causing proteins labeled as ‘undruggable.’ This change follows a $5.5 million Series Seed financing led by Medical Excellence Capital, aimed at scaling its proprietary Spiroligomer platform. Along with the rebranding, Eric Heil has been named CEO, and industry veterans David Scheer and Brian Halak, PhD, have joined the Board of Directors. This strategic realignment underscores Ladder Bio’s commitment to revolutionizing treatment for difficult-to-target diseases.
Philadelphia, PA – Ladder Bio Inc., formerly known as ThirdLaw Molecular, has unveiled a strategic rebranding to better align with its mission of developing innovative therapeutics targeting disease-causing proteins previously deemed “undruggable.” This transformation is accompanied by a $5.5 million Series Seed financing round, led by Medical Excellence Capital and supported by Hatch BioFund. The company has also appointed Eric Heil as Chief Executive Officer and expanded its Board of Directors to include industry veterans David Scheer and Brian Halak, PhD.
Ladder Bio’s proprietary Spiroligomer™ platform engineers structurally preorganized, sequence-defined “ladder-shaped” peptide-like molecules. These molecules are designed to combine the potency and specificity of biologics with the stability, oral availability, and cell penetration associated with small molecules. The company believes this approach could open new therapeutic pathways for conditions where current technologies have repeatedly fallen short.
The recent investment is expected to accelerate the scaling of the Spiroligomer platform, validate lead programs, initiate early in vitro studies, and expand the scientific and development teams. The leadership additions reflect decades of experience across biopharma company building, venture investing, and operational strategy—expertise the company expects will help guide its growth as it moves into the next stage of development.
Founded in 2020, Ladder Bio has been at the forefront of addressing the challenge of “undruggable” targets. The rebranding to Ladder Bio signifies a renewed commitment to pioneering Spiroligomer therapeutics, aiming to revolutionize the treatment landscape for diseases that have long evaded effective intervention.
Frequently Asked Questions (FAQ)
What is Ladder Bio Inc.?
Ladder Bio Inc., formerly known as ThirdLaw Molecular, is a biotechnology company focused on developing innovative therapeutics targeting disease-causing proteins previously considered “undruggable.” The company utilizes its proprietary Spiroligomer™ platform to create “ladder-shaped” peptide-like molecules that combine the advantages of biologics and small molecules.
What is the Spiroligomer™ platform?
The Spiroligomer™ platform is Ladder Bio’s proprietary technology that engineers structurally preorganized, sequence-defined “ladder-shaped” peptide-like molecules. These molecules are designed to deliver the potency and specificity of biologics along with the stability, oral availability, and cell penetration associated with small molecules, aiming to address disease targets that have been historically resistant to treatment.
Who are the new leadership appointments at Ladder Bio?
Ladder Bio has appointed Eric Heil as Chief Executive Officer. Additionally, industry veterans David Scheer and Brian Halak, PhD, have joined the company’s Board of Directors, bringing decades of experience in biopharma company building, venture investing, and operational strategy.
What is the significance of the $5.5 million Series Seed financing round?
The $5.5 million Series Seed financing round, led by Medical Excellence Capital and supported by Hatch BioFund, is expected to accelerate the scaling of the Spiroligomer platform, validate lead programs, initiate early in vitro studies, and expand the scientific and development teams. This investment underscores confidence in Ladder Bio’s innovative approach to tackling “undruggable” disease targets.
What does the rebranding to Ladder Bio signify?
The rebranding from ThirdLaw Molecular to Ladder Bio reflects the company’s renewed commitment to pioneering Spiroligomer therapeutics. It signifies a strategic shift to better align with the mission of developing new medicines for diseases that have long evaded effective intervention.
Key Features of Ladder Bio’s Recent Developments
| Feature | Description |
|---|---|
| Rebranding | Ladder Bio Inc. rebranded from ThirdLaw Molecular to better reflect its focus on developing therapeutics targeting “undruggable” disease targets. |
| Series Seed Financing | Closed a $5.5 million Series Seed financing round led by Medical Excellence Capital and supported by Hatch BioFund. |
| Leadership Appointments | Appointed Eric Heil as CEO and added David Scheer and Brian Halak, PhD, to the Board of Directors. |
| Spiroligomer™ Platform | Utilizes a proprietary platform to engineer “ladder-shaped” peptide-like molecules combining biologic potency with small molecule stability. |
| Investment Utilization | Funds will be used to scale the Spiroligomer platform, validate lead programs, initiate early in vitro studies, and expand teams. |
Deeper Dive: News & Info About This Topic
HERE Resources
Ladder Bio Inc. Launches Rebranding and Secures Funding
Verismo Therapeutics Named Top Workplace in Philadelphia for 2025
Doylestown’s Pennsylvania Biotechnology Center Opens New Opportunities
Author: STAFF HERE PHILADELPHIA WRITER
The PHILADELPHIA STAFF WRITER represents the experienced team at HEREPhiladelphia.com, your go-to source for actionable local news and information in Philadelphia, Philadelphia County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Mummers Parade, Philadelphia Flower Show, and Thanksgiving Day Parade. Our coverage extends to key organizations like the Greater Philadelphia Chamber of Commerce and United Way of Greater Philadelphia, plus leading businesses in telecommunications, food services, and healthcare that power the local economy such as Comcast, Aramark, and Children's Hospital of Philadelphia. As part of the broader HERE network, we provide comprehensive, credible insights into Pennsylvania's dynamic landscape.
